Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2020

The following table shows the warrant activity:

	Rollforward of Warrant Activity
		Warrants assumed and replaced in acquisition		Total
Balance as of December 31, 2019			—		—
Assumed and replaced			55,583.875		55,583.875
Exercised			—		—
Cancelled/Expired			—		—
Balance as of September 30, 2020			55,583.875		55,583.875

Schedule of Stock-Based Compensation Expense Recognized

Total stock-based compensation expense was recognized in our condensed consolidated statements of operations and comprehensive loss as follows (in thousands):

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2020		2019		2020		2019
Research and development	$	336	$	57	$	539	$	278
General and administrative		542		170		973		787
Total stock-based compensation	$	878	$	227	$	1,512	$	1,065

Below is the summary of the stock-based compensation expenses the Company incurred for three and nine months ended September 30, 2020:

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2020		2019		2020		2019
Amortization of outstanding equity-based awards	$	93	$	227	$	727	$	1,065
Modifications of terms related to grants previously issued to employees and board of directors		471		—		471		—
Amortization of equity-based awards assumed from the merger with Anelixis and replaced		38		—		38		—
New grants of preferred equity-based awards to directors and employees		276		—		276		—
Total stock-based compensation expense	$	878	$	227	$	1,512	$	1,065